

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
07 December 2023 (07.12.2023)



(10) International Publication Number

WO 2023/233301 A1

(51) International Patent Classification:

C07H 17/08 (2006.01) A61P 35/00 (2006.01)

A61K 31/7052 (2006.01) A61P 35/04 (2006.01)

(21) International Application Number:

PCT/IB2023/055545

(22) International Filing Date:

30 May 2023 (30.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/347,826 01 June 2022 (01.06.2022) US

(71) Applicant: LUNELLA BIOTECH, INC. [CA/CA]; 145
Richmond Road, Ottawa, Ontario K1Z 1A1 (CA).

(72) Inventors: LISANTI, Michael P.; 842 Wilmslow Road,
Flat 27, Philip Godlee Lodge, Didsbury Village Greater
Manchester M20 2DS (GB). SOTGIA, Federica; 842
Wilmslow Road, Flat 27, Philip Godlee Lodge, Didsbury
Village Greater Manchester M20 2DS (GB). OZSVARI,
Béla; 15 Maunby Gardens, Manchester Greater Manchester
M38 9LD (GB). KANGASMETSA, Jussi; 119 Clay Farm
Drive, Cambridge Cambridgeshire CB2 9BX (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.



(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

(54) Title: MACROLIDE SENOLYTIC COMPOUNDS

(57) Abstract: Disclosed herein are macrolide compounds having senolytic activity. These compounds selectively target senescent cells, and may be used to reduce or eradicate senescent cells in a subject, and/or delay the onset of aging. These compounds also inhibit propagation of cancer stem cells, and may be used to treat cancer, and in particular inhibit the propagation of cancer stem cells responsible for metastasis and tumor recurrence. Formulae (I) & (II):



WO 2023/233301 A1

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*